8.79
-0.09 (-1.01%)
| Previous Close | 8.88 |
| Open | 8.88 |
| Volume | 1,904,670 |
| Avg. Volume (3M) | 1,368,825 |
| Market Cap | 4,061,709,568 |
| Price / Sales | 0.970 |
| 52 Weeks Range | |
| Earnings Date | 1 May 2025 - 6 May 2025 |
| Profit Margin | -4.18% |
| Operating Margin (TTM) | 10.81% |
| Diluted EPS (TTM) | -0.380 |
| Quarterly Revenue Growth (YOY) | 18.40% |
| Quarterly Earnings Growth (YOY) | -49.70% |
| Current Ratio (MRQ) | 1.40 |
| Operating Cash Flow (TTM) | 295.10 M |
| Levered Free Cash Flow (TTM) | 253.45 M |
| Return on Assets (TTM) | 6.24% |
| Return on Equity (TTM) | -881.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amneal Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.10 |
|
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 50.78% |
| % Held by Institutions | 41.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blackbarn Capital Partners Lp | 31 Dec 2024 | 2,850,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DALY JASON B. | - | 8.76 | -46,936 | -411,159 |
| Aggregate Net Quantity | -46,936 | |||
| Aggregate Net Value ($) | -411,159 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DALY JASON B. | Officer | 06 Mar 2025 | Sell (-) | 46,936 | 8.76 | 411,159 |
| Date | Type | Details |
|---|---|---|
| 10 Mar 2025 | Announcement | Amneal to Participate at Upcoming Investor Conference |
| 03 Mar 2025 | Announcement | Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA |
| 28 Feb 2025 | Announcement | Amneal Reports Fourth Quarter and Full Year 2024 Financial Results |
| 19 Feb 2025 | Announcement | Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide |
| 29 Jan 2025 | Announcement | Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 |
| 23 Jan 2025 | Announcement | Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |